Vaccination  /  Future Value

Between 5 and 10 million Americans acquire pneumonia, 35 to 50 million are afflicted with influenza, and 1 million get herpes zoster (shingles)--each year. Older Americans are much more likely to get these infections and to suffer from complications and death. In fact, the death rate from pneumonia and influenza combined is close to 130 times higher in people age 85 and older, compared to people ages 45 to 54. Thankfully, vaccinations are available for many of the most common and deadly infectious disease in older Americans, and can save countless lives and healthcare dollars.

15 Matching Facts

Search matching Facts:
No results to display
    • Vaccines in development 2013
      Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
    • Vaccines in development 2013
      Vaccines in development for 2013  
    • Use of shingles vaccine could save $82 to $103 million
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Potential savings from shingles vaccine
      Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
    • Shingles vaccine could improve QALY and save money
      Vaccination of 1 million people age 60 and over with the shingles vaccine would result in 11,919 non-discounted and 8,782 discounted QALYs (quality of life years) gained and save around…  
    • Potential cost effectiveness of shingles vaccines
      The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…  
    • Cost-effectiveness of flu vaccine
      Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.  
    • Economic value from flu vaccine in elderly
      As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
    • Each flu case prevented could save $60 to $4,000
      The influenza vaccination could save between $60 and $4,000 per case prevented.  
    • Potential value of pneumonia vaccine
      Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4…  
    • Shingles vaccine would reduce healthcare use
      Use of the shingles vaccine in immunocompetent adults could eliminate more than 300,000 outpatient visits, 375,000 prescriptions, 9,700 emergency room visits, and 10,000 hospitalizations.  
    • ~One-third of shingles death preventable with vaccine
      Approximately one-third of shingles deaths may be preventable through vaccination.  
    • Annual flu vaccine could save 275,000 QALYs
      Offering the influenza vaccine annually to all people over the age of 50 would save around 275,000 quality-adjusted life years over the lifetimes of a birth cohort of 4 million.…  
    • Flu vaccine use can reduce illness risk in U.S. by 60%
      Recent studies from the Centers for Disease Control and Prevention show that the influenza vaccine can reduce the risk of illness in the overall U.S. population by around 60%. …  
    • Vaccines in development 2013
      137 vaccines are currently in development in the U.S. for infectious diseases.